Autopsy report · NCT04106167

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

“This study was terminated by the Sponsor.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 4 years 2 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Fate Therapeutics

Sponsor type

Industry

Conditions

Advanced Solid Tumor; Lymphoma; Gastric Cancer; Colorectal Cancer; Head and Neck Cancer; Squamous Cell Carcinoma

Interventions

Allogeneic natural killer (NK) cell

Participants

20

Sites

4

Countries

United States

Trials that died the same way

• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
  “The study was terminated by the sponsor” (98% match in meaning)
• Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
  “The Sponsor terminated the study.” (96% match in meaning)
• A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
  “The study was terminated early as per Sponsor's decision” (94% match in meaning)
• Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
  “Study terminated by the Sponsor” (93% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.